PLAY PODCASTS
Cutting-Edge Concepts in HIV Care: PrEP
Episode 214

Cutting-Edge Concepts in HIV Care: PrEP

Listen to Paul E. Sax, MD, discuss the latest recommendations and options for HIV pre-exposure prophylaxis.

Decera Clinical Education Infectious Disease Podcast · Paul E. Sax MD

November 14, 202213m 58s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode, Paul E. Sax, MD, discusses the latest recommendations and options for HIV pre-exposure prophylaxis (PrEP), including:

  • CDC PrEP guideline 2021 updates for oral PrEP
  • The ANRS IPERGAY study: on-demand oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) PrEP in men who have sex with men who are at high risk for HIV infection
  • A review of the HPTN 083 and 084 studies: efficacy and safety of long-acting (LA) injectable cabotegravir (CAB) vs daily oral FTC/TDF for PrEP
  • 1-year follow-up after unblinding for HPTN 083 and 084
  • LA CAB for PrEP: monitoring and safety
  • Stopping LA CAB for PrEP

Presenter: 

Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Link to full program:
https://bit.ly/3VIsDTg

Follow along with the slides at:
https://bit.ly/3Gh9AKG


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

transgender womenamprep studycabotegravircabhptn 083anrs ipergay2-1-1on-demandpreexposure prophylaxishptn 084cisgender womentenofovir alafenamidemsmhiv-1 rna2:1:1prepprep monitoringinitiating prepftcstopping prepmen who have sex with menprep initiationtenofovir disoproxil fumarateemtricitabinetdfdelayed diagnosisemtricitabine/tenofovirftc/tdforal therapyftc/taftgwtafhiv